BACKGROUND: Activating mutations in RAS are frequently present in patients with acute myeloid leukemia (AML), but their overall prognostic impact is not clear. METHODS: A retrospective analysis was performed to establish the clinical characteristics of patients with RAS-mutated (RAS(mut) ) AML, to analyze their outcome by therapy, and to describe the proteomic profile of RAS(mut) compared with wild-type RAS (RAS(WT) ) AML. RESULTS: Of 609 patients with newly diagnosed AML, 11% had RAS(mut) . Compared with RAS(WT) , patients with RAS(mut) AML were younger (median age, 54 years vs 63 years; P = .001), had a higher white blood cell count (16K mm(-3) vs 4K mm(-3) ; P < 0.001) and bone marrow blast percentage (56% vs 42%; P = .01) at diagnosis, and were less likely to have an antecedent hematologic disorder (36% vs 50%; P = .03). The inv(16) karyotype was overrepresented in patients with RAS(mut) and the -5 and/or -7 karyotype was underrepresented. RAS mutations were found to have no prognostic impact on overall survival or disease-free survival overall or within cytogenetic subgroups. There was a suggestion that patients with RAS(mut) benefited from cytarabine (AraC)-based therapy. Proteomic analysis revealed simultaneous upregulation of the RAS-Raf-MAP kinase and phosphoinositide 3-kinase (PI3K) signaling pathways in patients with RAS(mut) . CONCLUSIONS: RAS mutations in AML may delineate a subset of patients who benefit from AraC-based therapy and who may be amenable to treatment with inhibitors of RAS and PI3K signaling pathways.
BACKGROUND: Activating mutations in RAS are frequently present in patients with acute myeloid leukemia (AML), but their overall prognostic impact is not clear. METHODS: A retrospective analysis was performed to establish the clinical characteristics of patients with RAS-mutated (RAS(mut) ) AML, to analyze their outcome by therapy, and to describe the proteomic profile of RAS(mut) compared with wild-type RAS (RAS(WT) ) AML. RESULTS: Of 609 patients with newly diagnosed AML, 11% had RAS(mut) . Compared with RAS(WT) , patients with RAS(mut) AML were younger (median age, 54 years vs 63 years; P = .001), had a higher white blood cell count (16K mm(-3) vs 4K mm(-3) ; P < 0.001) and bone marrow blast percentage (56% vs 42%; P = .01) at diagnosis, and were less likely to have an antecedent hematologic disorder (36% vs 50%; P = .03). The inv(16) karyotype was overrepresented in patients with RAS(mut) and the -5 and/or -7 karyotype was underrepresented. RAS mutations were found to have no prognostic impact on overall survival or disease-free survival overall or within cytogenetic subgroups. There was a suggestion that patients with RAS(mut) benefited from cytarabine (AraC)-based therapy. Proteomic analysis revealed simultaneous upregulation of the RAS-Raf-MAP kinase and phosphoinositide 3-kinase (PI3K) signaling pathways in patients with RAS(mut) . CONCLUSIONS: RAS mutations in AML may delineate a subset of patients who benefit from AraC-based therapy and who may be amenable to treatment with inhibitors of RAS and PI3K signaling pathways.
Authors: Jianhua Hu; Xuming He; Keith A Baggerly; Kevin R Coombes; Bryan T J Hennessy; Gordon B Mills Journal: Bioinformatics Date: 2007-06-28 Impact factor: 6.937
Authors: Raoul Tibes; Yihua Qiu; Yiling Lu; Bryan Hennessy; Michael Andreeff; Gordon B Mills; Steven M Kornblau Journal: Mol Cancer Ther Date: 2006-10 Impact factor: 6.261
Authors: H Kiyoi; T Naoe; Y Nakano; S Yokota; S Minami; S Miyawaki; N Asou; K Kuriyama; I Jinnai; C Shimazaki; H Akiyama; K Saito; H Oh; T Motoji; E Omoto; H Saito; R Ohno; R Ueda Journal: Blood Date: 1999-05-01 Impact factor: 22.113
Authors: David T Bowen; Marion E Frew; Robert Hills; Rosemary E Gale; Keith Wheatley; Michael J Groves; Stephen E Langabeer; Panagiotis D Kottaridis; Anthony V Moorman; Alan K Burnett; David C Linch Journal: Blood Date: 2005-06-09 Impact factor: 22.113
Authors: Jeffrey W Tyner; Heidi Erickson; Michael W N Deininger; Stephanie G Willis; Christopher A Eide; Ross L Levine; Michael C Heinrich; Norbert Gattermann; D Gary Gilliland; Brian J Druker; Marc M Loriaux Journal: Blood Date: 2008-12-15 Impact factor: 22.113
Authors: Steven M Kornblau; Raoul Tibes; Yi Hua Qiu; Wenjing Chen; Hagop M Kantarjian; Michael Andreeff; Kevin R Coombes; Gordon B Mills Journal: Blood Date: 2008-10-07 Impact factor: 22.113
Authors: Andreas Neubauer; Kati Maharry; Krzysztof Mrózek; Christian Thiede; Guido Marcucci; Peter Paschka; Robert J Mayer; Richard A Larson; Edison T Liu; Clara D Bloomfield Journal: J Clin Oncol Date: 2008-06-16 Impact factor: 44.544
Authors: P Y Mak; D H Mak; H Mu; Y Shi; P Ruvolo; V Ruvolo; R Jacamo; J K Burks; W Wei; X Huang; S M Kornblau; M Andreeff; B Z Carter Journal: Apoptosis Date: 2014-04 Impact factor: 4.677
Authors: Andres Jerez; Michael J Clemente; Hideki Makishima; Hanna Rajala; Ines Gómez-Seguí; Thomas Olson; Kathy McGraw; Bartlomiej Przychodzen; Austin Kulasekararaj; Manuel Afable; Holleh D Husseinzadeh; Naoko Hosono; Francis LeBlanc; Sonja Lagström; Dan Zhang; Pekka Ellonen; André Tichelli; Catherine Nissen; Alan E Lichtin; Aleksandra Wodnar-Filipowicz; Ghulam J Mufti; Alan F List; Satu Mustjoki; Thomas P Loughran; Jaroslaw P Maciejewski Journal: Blood Date: 2013-08-07 Impact factor: 22.113
Authors: Zhen Zhao; Chi-Chao Chen; Cory D Rillahan; Ronglai Shen; Thomas Kitzing; Megan E McNerney; Ernesto Diaz-Flores; Johannes Zuber; Kevin Shannon; Michelle M Le Beau; Mona S Spector; Scott C Kogan; Scott W Lowe Journal: Nat Genet Date: 2015-03-30 Impact factor: 38.330
Authors: I Gómez-Seguí; H Makishima; A Jerez; K Yoshida; B Przychodzen; S Miyano; Y Shiraishi; H D Husseinzadeh; K Guinta; M Clemente; N Hosono; M A McDevitt; A R Moliterno; M A Sekeres; S Ogawa; J P Maciejewski Journal: Leukemia Date: 2013-06-14 Impact factor: 11.528